TY - JOUR
T1 - CSF phosphorylated tau as an indicator of subsequent tau accumulation
AU - Cogswell, Petrice M.
AU - Wiste, Heather J.
AU - Mielke, Michelle M
AU - Schwarz, Christopher
AU - Weigand, Stephen D.
AU - Lowe, Val J.
AU - Therneau, Terry M.
AU - Knopman, David S
AU - Graff-Radford, Jonathan
AU - Vemuri, Prashanthi
AU - Senjem, Matthew L.
AU - Gunter, Jeffrey L.
AU - Algeciras-Schimnich, Alicia
AU - Petersen, Ronald C.
AU - Jack, Clifford R Jr.
N1 - Funding Information:
We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV-1451 precursor, chemistry production advice, and FDA regulatory cross-filing permission and documentation needed for this work. This work was supported by the National Institutes of Health [ U01 AG006786, P50 AG016574, R37 AG011378, RO1 AG041851, R01 NS097495, R01 AG056366 ].
Funding Information:
We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying AV-1451 precursor, chemistry production advice, and FDA regulatory cross-filing permission and documentation needed for this work. This work was supported by the National Institutes of Health [U01 AG006786, P50 AG016574, R37 AG011378, RO1 AG041851, R01 NS097495, R01 AG056366].
Publisher Copyright:
© 2022
PY - 2022/9
Y1 - 2022/9
N2 - We evaluated the relationship between baseline CSF p-tau181 and the rate of tau PET change in the temporal meta-ROI and entorhinal cortex (ERC) and how it varied by amyloid level (CSF Aβ42 or amyloid PET) among 143 individuals from the Mayo Clinic Study of Aging and Mayo Alzheimer Disease Research Center. Higher CSF p-tau181, lower CSF Aβ42, and higher amyloid PET levels were associated with faster rates of tau PET change in both the temporal meta-ROI and ERC. In the temporal meta-ROI, longitudinal tau PET accumulation occurred primarily in participants with abnormal biomarker levels and a diagnosis of dementia, which supports the hypothesis that tau aggregation begins later in the disease process. Compared to the temporal meta-ROI, the ERC showed greater change in tau PET in non-demented participants but less change in later disease stages, supporting ERC as a more sensitive marker of early tau PET changes but with less dynamic range over the disease spectrum. We found both amyloid and CSF p-tau181 were associated with rates of tau PET change but there were some differences in associations by region, amyloid biomarker, and disease stage.
AB - We evaluated the relationship between baseline CSF p-tau181 and the rate of tau PET change in the temporal meta-ROI and entorhinal cortex (ERC) and how it varied by amyloid level (CSF Aβ42 or amyloid PET) among 143 individuals from the Mayo Clinic Study of Aging and Mayo Alzheimer Disease Research Center. Higher CSF p-tau181, lower CSF Aβ42, and higher amyloid PET levels were associated with faster rates of tau PET change in both the temporal meta-ROI and ERC. In the temporal meta-ROI, longitudinal tau PET accumulation occurred primarily in participants with abnormal biomarker levels and a diagnosis of dementia, which supports the hypothesis that tau aggregation begins later in the disease process. Compared to the temporal meta-ROI, the ERC showed greater change in tau PET in non-demented participants but less change in later disease stages, supporting ERC as a more sensitive marker of early tau PET changes but with less dynamic range over the disease spectrum. We found both amyloid and CSF p-tau181 were associated with rates of tau PET change but there were some differences in associations by region, amyloid biomarker, and disease stage.
KW - Alzheimer Disease
KW - amyloid
KW - CSF p-tau
KW - tau PET
UR - http://www.scopus.com/inward/record.url?scp=85133815231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133815231&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2022.02.015
DO - 10.1016/j.neurobiolaging.2022.02.015
M3 - Article
C2 - 35764037
AN - SCOPUS:85133815231
VL - 117
SP - 189
EP - 200
JO - Neurobiology of Aging
JF - Neurobiology of Aging
SN - 0197-4580
ER -